alexgreat replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
Stock still holding in, for sure needed some consolidation, yesterdays news
2017-12-13 10:55 ET - News Release
Mr. Alex Blanchard reports
LEXARIA BIOSCIENCE RECEIVES U.S. PATENT AWARD FOR ITS DEHYDRATECH(TM) DELIVERY OF THC, NSAIDS, NICOTINE AND VITAMINS
The United States Patent and Trademark Office (USPTO) has granted patent No. 9,839,612 B2 to Lexaria Bioscience Corp. for the use of DehydraTech technology as a delivery platform for a wide variety of active pharmaceutical ingredients (APIs) including all cannabinoids including tetrahydrocannabinol; fat soluble vitamins; non-steroidal anti-inflammatory pain medications (NSAIDs); and nicotine.
This granted patent completes the patent allowance process that was announced on Oct. 31, 2017, and this patent grant is now final. The title of the granted patent is "Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof." This issued patent protects Lexaria's intellectual property (IP) for the DehydraTech delivery of all the active substances noted via nearly any kind of processed food or beverage as well as capsules and pills.
In one aspect a method of treating a condition is provided wherein a cannabinoid is used to treat conditions selected from the group consisting of cardiac diseases such as heart disease, ischemic infarcts and cardiometabolic disorders; neurological diseases such as Alzheimer's disease, Parkinson's disease, schizophrenia and human immunodeficiency virus (HIV) dementia; obesity; metabolic disorders such as insulin related deficiencies and lipid profiles, hepatic diseases, diabetes and appetite disorders; cancer chemotherapy, benign prostatic hypertrophy; irritable bowel syndrome, biliary diseases; ovarian disorders; marijuana abuse; and alcohol, opioid, nicotine or cocaine addiction.
Lexaria also continues to advance all of its additional patent applications in various countries as it levers patent success in the United States. For example, some of the company's patent applications have recently entered the active patent investigation phase in China, the European Union and in Canada.
"Lexaria has now locked up the IP for its next-generation drug delivery system," said chief executive officer Chris Bunka. "This groundbreaking, patented IP builds a foundation for new business opportunities in 2018 including what could be the world's first nicotine edibles for the smokeless tobacco industry, or improved new products for NSAID-derived pain management, as well as in the rapidly growing cannabis market."
Lexaria's patented DehydraTech technology is focused on improved delivery methodologies of many commonly used API substances. As such, it provides an additional layer of effectiveness that is designed to harmonize with the intellectual property of third parties. Both patented and generic API substances can utilize Lexaria's patented technology. Lexaria's long-term strategy is to partner with the world's leading firms as they deliver best-of-class products to their existing large consumer groups.
Lexaria is presently investigating and will continue to pursue additional technologies that could deliver value to its growing portfolio of patented technologies.
lynnsa10 replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
I added a little yesterday, amazing. I can find no news but I do like the last news release.
Lexaria does not say why trading is up
2017-12-08 13:11 ET - News Release
An anonymous director reports
LEXARIA ANNOUNCES NO MATERIAL DEVELOPMENTS
At the request of the Investment Industry Regulatory Organization of Canada, Lexaria Bioscience Corp. is not aware of any undisclosed material change to the corporation's business or operations and it has no material change to report at this time. Lexaria conducts technology licence sales activities as part of its everyday business activities and will disclose all material sales and licensing agreements if and as they occur.
GoldnBoy replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
DJ, that is the thing with politicians. you cannot rely on them to do anything, but another reason I like LXX, they are not tied or effected much by the legalization timeline in Canada, they can be diversified in US, elsewhere and the medical side too